About CCR – Program Offices
Within CCR’s Office of the Director, several sub-offices have been set up to provide specific support in these critical program areas:
Animal Resource Program – CCR’s Animal Resource Program is the central point-of-contact for all CCR animal-related issues. This Office offers guidance, training and education, imaging, and technology development for those CCR investigators who work (or plan to work) with animal models.
Office of Communications – Communicates the importance of CCR’s ongoing basic, translational, and clinical research to both inside the Center and to a variety of outside audiences.
Office of Policy and Intellectual Property (OPIP) – Assists the Director in building partnerships that enhance CCR’s research program while maintaining compliance with applicable policy and regulations.
Office of Science & Technology Partnerships (OSTP) – Introduces new technologies and resources to our researchers through partnerships, collaborations, and technology transfer agreements with outside organizations, including the private sector.
Office of Scientific Programs – Provides support to CCR investigators for site visit reviews, annual reporting, scientific awards, promotions, and recruitment of high-quality postdoctoral and clinical fellows. This office also coordinates the quadrennial review process for all CCR staff clinicians and staff scientists.
Office of Training and Education – Supports and enhances the overall training experience of CCR’s postdoctoral and clinical fellows and assists our investigators in recruiting outstanding postdoctoral candidates.
Office of the Clinical Director (OCD) –This office provides support for all NCI-CCR clinical trials, which are conducted at the new NIH Clinical Center in Bethesda, Maryland. Activities in this office focus on patient recruitment and care, oncology nursing, preparation of new clinical protocols for review by the Institutional Review Board (IRB), biostatistics and data management, and ongoing education and training for staff members. The goal is to provide the highest standard-of-care for cancer patients who are participating in Phase I and II clinical trials at the Center.
